Skip to content

FOXA1 transcriptionally upregulates LMAN2 to promote breast cancer progression.

Aug 2026 · Tissue & Cell · Vol 104 Pt 2, pp. 103883 · 0 citations · 43 references
Medicine

TL;DR

FoxA1 bound to the LMAN2 promoter to enhance its transcription, thereby promoting BC progression at least partially through ferroptosis suppression and malignant phenotype induction.

Abstract

Background

Breast cancer (BC), the most widespread malignancy in women globally, is characterized by complex and heterogeneous mechanisms. Lectin, mannose binding 2 (LMAN2), a potential oncogene highly expressed in BC, is linked to poor prognosis. The transcription factor forkhead box protein A1 (FOXA1) is often overexpressed in BC and tied to malignant phenotypes, but how it regulates LMAN2 to influence BC progression remains unclear.

Methods

LMAN2 expression in BC and its association with patient prognosis were analyzed via the GEPIA database. mRNA and protein levels were detected by qRT-PCR and Western blot. Cell proliferation, angiogenesis, invasion/migration, and apoptosis were evaluated using EdU, tube formation assay, Transwell, and flow cytometry. The ferroptosis status of cells was assessed by detecting ferroptosis-related indicators. The transcriptional regulatory effect of FOXA1 on LMAN2 was verified using JASPAR database, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays. The in vivo effect of the FOXA1/LMAN2 axis on BC growth was validated using a nude mouse xenograft model, and related protein expression was detected by immunohistochemistry (IHC).

Results

LMAN2 was upregulated in BC, with high expression linked to poor survival. Silencing LMAN2 was associated with reduced BC cell proliferation, migration, invasion, and angiogenesis, concomitant with increased ferroptosis and apoptosis. FOXA1 binding sites were identified in the LMAN2 promoter; FOXA1 directly bound to this region to enhance LMAN2 transcription, and FOXA1 knockdown reduced LMAN2 expression. FOXA1 overexpression enhanced BC cell malignancy and suppressed ferroptosis, with these effects reversed by concurrent LMAN2 silencing. In vivo, FOXA1 knockdown restrained xenograft tumor growth, and this effect was reversed by concurrent LMAN2 overexpression.

Conclusion

FOXA1 bound to the LMAN2 promoter to enhance its transcription, thereby promoting BC progression at least partially through ferroptosis suppression and malignant phenotype induction.

View source

Similar papers

Open access Aug 2026

Transcription Factor ELF3 Promotes Cervical Cancer Progression via Transcriptional Upregulation of GMPS

It is demonstrated that ELF3 functions as an oncogenic transcription factor in CC by upregulating GMPS, thereby enhancing proliferation and migration and restraining ferroptosis and targeting the ELF3/GMPS axis represents a promising therapeutic strategy for CC.

Yuan-Yuan Zhang, Shaliya Abuduwufu, Qian Zhuo et al. · 0 citations
Open access Sep 2026

XPR1 Promotes the Malignant Phenotypes of Thyroid Carcinoma Cells Partly Through NF-κB-Related Signaling

The results suggest that the pro-tumorigenic effects of XPR1 in thyroid carcinoma cells, manifested by increased cell growth, motility, invasiveness, and reduced susceptibility to apoptosis, may be partly associated with NF-κB signaling.

J. You, Tong-Xin Zou, Bo-Xiu Wang et al. · 0 citations
Aug 2026

HOXC9 transcriptionally activates NRP1 to promote cell malignant progression and immune evasion in colorectal cancer

A specific mechanism whereby HOXC9 transcriptionally activates NRP1 is elucidated, thereby contributing to CRC malignant development and immune evasion and elucidate a specific mechanism whereby NRP1 overexpression could reverse CRC progression inhibition and immune function enhancement caused by HOXC9 downregulation.

Xiaofeng Qiu, Sheng Hu, Bingling Liao et al. · 0 citations
Open access Sep 2026

Transcription factor KLF4 suppresses the malignant progression of colorectal cancer by activating ETFDH transcription.

Colorectal cancer (CRC) is a common cause of cancer-related deaths worldwide. Electron transfer flavoprotein dehydrogenase (ETFDH) is a novel prognostic biomarker for human CRC. However, the role and molecular mechanism of ETFDH in CRC are still unclear. DEGs in CRC development were identified using mRNA microarray dat...

Yan Zeng, Qiao-Zhen Liu, Ya-Li Xu et al. · 0 citations
Open access Sep 2026

RNA-Binding Protein CSTF2 Drives Immune Evasion and Malignant Progression in Breast Cancer by Degrading THSD1 mRNA

This study delineates the detailed molecular mechanisms by which the RBP CSTF2 exacerbates malignant progression in BC, offering fresh theoretical insights and potential targets for targeted immunotherapeutic strategies in BC.

Tangxiaoman Wang, Lei Yan, Jia-Li Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.